Sulfurous Eructation During GLP-1 Agonist Therapy: Mechanistic Rationale for Bismuth Subsalicylate

Key Points

• This research aims to evaluate the reasons and clinical benefits for using bismuth subsalicylate during GLP-1 agonist therapy to manage sulfurous eructation.
• Synthesis of existing evidence regarding GLP-1 and dual receptor agonists.
• Assessment of bismuth subsalicylate's role in treating gastrointestinal side effects.
• Exploration of mechanistic pathways behind sulfurous eructation.
• Identified potential causes of sulfurous eructation linked to GLP-1 therapies.
• Suggests bismuth subsalicylate may alleviate these gastric symptoms.
• Highlights the need for further clinical investigation into bismuth subsalicylate's effectiveness.